However, there has been no clear evidence to support the inhibition of cardiovascular events or diabetic nephropathy by DPP-4 inhibitors [17–20], although the glucose-lowering efficacy of DPP-4 inhibitors in patients with type 2 diabetes is better in Asians than in other ethnic groups [21]. This evidence concerns the gene DPP4 and diabetic kidney disease.